To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Clinical trial NCT04853342 · RECRUITING
Trial details
- NCT number
- NCT04853342
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-07
- Primary completion
- 2026-12-01
- Enrollment
- 318
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.